Andere talen Visioneering Technologies, Inc.

Aandelen

VTI

AU000000VTI2

Beurs gesloten - Australian S.E. Andere beurzen 08:10:46 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,16 ^AUD	-3,03%		-8,57%	-36,00%

28/02	Visioneering Technologies, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
05/01	Visioneering Technologies geeft deel van tekort uit claimemissie uit	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study	19/01
Visioneering Technologies Issues Part of Shortfall from Rights Offering	05/01
VTI gibt positive vorläufige 1-Jahres-Daten aus der klinischen PROTECT-Studie auf der Jahrestagung der American Academy of Optometry bekannt	13-10-23
VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting	12-10-23
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion	10-10-23
VTI Appoints Dr. Juan Carlos Aragón as CEO and Executive Director	30-08-23
Visioneering Technologies Appoints CEO	29-08-23
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023	29-08-23
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023	29-08-23
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	17-08-23
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal	13-03-23
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27-02-23
Visioneering Technologies, Inc. Announces Board Changes	19-12-22
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial	07-12-22
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT	06-12-22
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	23-08-22
Visioneering Technologies : Appendix 4C and Business Activity Report - Jun-22 Qtr	19-07-22
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial	13-07-22
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control	13-07-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Visioneering Technologies, Inc.

Aandelen

VTI

AU000000VTI2

Andere talen

Filters